Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annals of Oncology

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdv326PMID 26216388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

  2015cited by this paper
• Reliability of maximal cardiopulmonary exercise testing in men with prostate cancer.

  2015cited by this paper
• Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

  2014cited by this paper
• Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Managing bone metastases and reducing skeletal related events in prostate cancer

  2014cited by this paper
• Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.

  2014cited by this paper
• Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study.

  2014cited by this paper
• Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

  2014cited by this paper
• Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.

  2014cited by this paper
• A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR.

  2014cited by this paper
• Visceral disease in castration-resistant prostate cancer.

  2014cited by this paper
• Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer

  2014cited by this paper
• Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.

  2014cited by this paper
• A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy

  2013cited by this paper
• Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

  2013cited by this paper
• Frailty in elderly people.

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

  2013cited by this paper
• Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.

  2013cited by this paper
• Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer

  2013cited by this paper
• Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa): Results of a Multi-institutional Randomized Prospective Clinical Trial

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

  2013cited by this paper
• 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

  2013cited by this paper
• A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer

  2013cited by this paper
• Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

  2013cited by this paper
• Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.

  2013cited by this paper
• Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

  2013cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Predictive Factors for Premature Discontinuation of Docetaxel-Based Systemic Chemotherapy in Men With Castration-Resistant Prostate Cancer

  2013cited by this paper
• Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

  2013cited by this paper
• Toward patient-centered drug development in oncology.

  2013cited by this paper
• Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.

  2013cited by this paper
• A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

  2013cited by this paper
• The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration

  2013cited by this paper
• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2013cited by this paper
• Exploring physical activity level in patients with thoracic cancer: implications for use as an outcome measure

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer

  2012cited by this paper
• EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone

  2012cited by this paper
• Dasatinib combined with docetaxel for castration‐resistant prostate cancer

  2012cited by this paper
• Prediction of survival benefit using an automated bone scan index in patients with castration‐resistant prostate cancer

  2012cited by this paper
• Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature

  2012cited by this paper
• Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

  2012cited by this paper
• Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy?

  2012cited by this paper
• Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

  2012cited by this paper
• Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.

  2012cited by this paper
• Consensus-based standards for best supportive care in clinical trials in advanced cancer.

  2012cited by this paper
• Obesity, body composition, and prostate cancer

  2012cited by this paper
• Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy

  2012cited by this paper
• Prognostic Value of Body Mass Index in Korean Patients with Castration-Resistant Prostate Cancer

  2012cited by this paper
• The Exercising Together project: design and recruitment for a randomized, controlled trial to determine the benefits of partnered strength training for couples coping with prostate cancer.

  2012cited by this paper
• Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study

  2012cited by this paper
• The Impact of an Outpatient Palliative Care Consultation on Symptom Burden in Advanced Prostate Cancer Patients

  2012cited by this paper
• Sarcopenia during androgen-deprivation therapy for prostate cancer.

  2012cited by this paper
• Definition and classification of cancer cachexia: an international consensus.

  2011cited by this paper
• Pain in castration-resistant prostate cancer with bone metastases: a qualitative study

  2011cited by this paper
• Impact of docetaxel‐based chemotherapy on quality of life of patients with castration‐resistant prostate cancer: results from a prospective phase II randomized trial

  2011cited by this paper
• Prognostic impact of abdominal adiposity, waist circumference and body mass index in patients with intermediate-risk prostate cancer treated with radiotherapy

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol

  2011cited by this paper
• Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

  2011cited by this paper
• Evaluation of a Body-Worn Sensor System to Measure Physical Activity in Older People With Impaired Function

  2011cited by this paper
• Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia.

  2011cited by this paper
• The CT flare response of metastatic bone disease in prostate cancer

  2011cited by this paper
• Establishing a cancer nutrition rehabilitation program (CNRP) for ambulatory patients attending an Australian cancer center

  2011cited by this paper
• Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

  2011cited by this paper
• Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI).

  2011cited by this paper
• Response burden and questionnaire length: is shorter better? A review and meta-analysis.

  2011cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Leptin increases prostate cancer aggressiveness

  2011cited by this paper
• Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination

  2011cited by this paper
• Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response

  2011cited by this paper
• Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib

  2011cited by this paper
• Imaging , Diagnosis , Prognosis Prognostic Value of Baseline [ 18 F ] Fluorodeoxyglucose Positron Emission Tomography and 99 mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer

  2010cited by this paper
• Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology

  2010cited by this paper
• FDA guidance on patient reported outcomes

  2010cited by this paper
• Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients.

  2010cited by this paper
• A phase II trial of weekly i.v. KW‐2170 in advanced castrate‐resistant prostate cancer

  2010cited by this paper
• Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

  2010cited by this paper
• Development of symptom assessments utilising item response theory and computer-adaptive testing--a practical method based on a systematic review.

  2010cited by this paper
• Samarium-153 treatment of bone pain in patients with metastatic prostate cancer.

  2010cited by this paper
• Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation

  2009cited by this paper
• Strength of skeletal muscle and quality of life in patients suffering from “typical male” carcinomas

  2009cited by this paper
• Improvement in Sensory Pain Rating After Palliative Systemic Radionuclide Therapy in Patients With Advanced Prostate Cancer

  2009cited by this paper
• Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

  2009cited by this paper

• Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer.

  2022cites this paper
• A Systematic Review of the Treatment Outcomes among Prostate Cancer Patients in Africa

  2022cites this paper
• Development and initial clinical correlation of a DNA methylation‐based blood test for prostate cancer

  2020cites this paper
• Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review

  2019cites this paper
• The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone.

  2019cites this paper
• Identification of genes associated with castration-resistant prostate cancer by gene expression profile analysis

  2017influential citation
• The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use

  2017cites this paper
• Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.

  2017cites this paper
• CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3

  2016cites this paper
• The oncologists’ unmet clinical needs for imaging in advanced prostate cancer

  2016cites this paper